Semaglutide Dosage Guide: Research Protocol, Reconstitution & Timing (2026)

# Semaglutide Dosage Guide: Research Protocol, Reconstitution & Timing (2026)

> Research Disclaimer: This guide is for educational and research purposes only. Semaglutide is an FDA-approved prescription medication (Ozempic NDA 209637; Wegovy NDA 215256; Rybelsus NDA 213051). All dosing schedules referenced here are drawn from published peer-reviewed clinical trial literature. This is not medical advice. Do not use this information to self-administer any substance. Research use only (RUO).

Semaglutide is the most comprehensively studied GLP-1 receptor agonist in modern peptide pharmacology. Since its approval, it has accumulated more peer-reviewed outcome data than virtually any other peptide compound — spanning glycemic control, weight management, cardiovascular risk reduction, and emerging applications in neuroinflammation and kidney protection.

For researchers sourcing lyophilized semaglutide, a detailed working protocol is essential: reconstitution errors can denature the peptide; dosing schedule deviations can invalidate comparative studies; poor storage conditions shorten vial viability from weeks to days.

This guide synthesizes data from the SUSTAIN, STEP, and SELECT clinical programs, FDA package inserts (Ozempic PI rev. 2023, Wegovy PI rev. 2023), and published pharmacokinetic literature to give researchers a scientifically grounded, practical reference.

For pricing and supplier comparison across 20+ verified vendors, visit our semaglutide supplier comparison page.

For a comprehensive mechanism and research background overview, see the Semaglutide Research Guide 2026.

---

1. What Is Semaglutide? A Brief Research Recap

Semaglutide is a 29-amino-acid GLP-1 receptor agonist developed by Novo Nordisk with 94% structural homology to endogenous GLP-1(7-36) amide. Its extended half-life of approximately 165-184 hours — enabling once-weekly dosing — is achieved through three structural modifications:

1. Amino acid substitution at position 8 — Aib (aminoisobutyric acid) replaces alanine, conferring DPP-4 protease resistance

2. Linker and C-18 fatty diacid chain at Lys26 — enables reversible albumin binding, extending circulation time

3. Two amino acid substitutions (Arg34Lys, Lys26Arg) — reduce receptor cross-reactivity

These modifications produce a half-life roughly 10x longer than native GLP-1, making once-weekly subcutaneous dosing pharmacokinetically sound.

FDA-approved forms:

Research-grade lyophilized semaglutide is available from multiple vendors as freeze-dried powder in 2 mg, 5 mg, and 10 mg vials. Unlike the commercial pen formulations, these require reconstitution before use in laboratory or in vivo research settings.

---

2. Reconstitution Guide for Research-Grade Semaglutide Powder

Reconstitution quality directly determines data quality. Aggregated peptide or denatured protein will not bind GLP-1 receptors with the same affinity as properly prepared solution, introducing systematic error into dose-response curves.

Materials Required

• •Lyophilized semaglutide vial (2 mg, 5 mg, or 10 mg)
• •Bacteriostatic water for injection (0.9% benzyl alcohol) — preferred for multi-use vials requiring storage of 28 days or more
• •Sterile water for injection — acceptable for single-use or same-day-use applications
• •1 mL insulin syringe (U-100, 29-31 gauge needle)
• •Alcohol swabs (70% isopropyl)
• •Refrigerator (2-8 degrees C / 36-46 degrees F) for post-reconstitution storage

Step-by-Step Reconstitution Protocol

Step 1 — Inspect the vial

Check for visible particulates, discoloration, or vial integrity. Lyophilized semaglutide should appear as a white to off-white powder. Discard any vial with visible contamination or compromised septum.

Step 2 — Prepare aseptic workspace

Clean your work surface. Wipe the vial septum with a fresh alcohol swab. Allow 30 seconds to air-dry before inserting a needle. Never inject through a wet septum.

Step 3 — Calculate reconstitution volume

The reconstitution volume determines your working concentration. Common targets:

For most research applications, 1.0 mg/mL is a convenient working concentration that simplifies volume calculations (1 mcg/dose = 0.001 mL of working solution).

Step 4 — Add diluent slowly

Draw up the calculated volume of bacteriostatic water into your syringe. Insert the needle into the vial at an angle and direct the stream of water gently down the side of the vial — not directly onto the lyophilized cake. This minimizes foaming and mechanical denaturation.

Step 5 — Allow passive dissolution

Do NOT shake the vial. Gently swirl or roll the vial between your palms for 30-60 seconds. Allow it to sit at room temperature for 5-10 minutes. The powder should dissolve to form a clear, colorless to faintly yellow solution.

Step 6 — Inspect before use

Examine the reconstituted solution. It should be clear with no visible particles or cloudiness. A slightly yellowish tint is normal for semaglutide. Do not use if cloudy, precipitated, or discolored beyond pale yellow.

Step 7 — Label and refrigerate immediately

Label the vial with: compound name, concentration, reconstitution date, and expiry (28 days from reconstitution for bacteriostatic water diluent). Store at 2-8 degrees C.

---

3. Subcutaneous Injection Protocol

All published clinical research on subcutaneous semaglutide uses a standardized injection technique. The following is adapted from FDA-approved prescribing information.

Injection Sites

The three approved subcutaneous injection sites are:

1. Abdomen — 2 inches from the navel in any direction; most common site in clinical trials

2. Upper thigh (anterolateral) — outer front surface of either thigh

3. Upper arm (lateral) — back of upper arm (requires a second person or mirror assistance)

Site rotation: Rotate injection sites each week within the same anatomical region to prevent lipohypertrophy. Do not inject into the same exact spot twice consecutively.

Injection Technique (Standard)

1. Wipe the chosen site with an alcohol swab; air-dry for 30 seconds

2. With a 29-31 gauge, 4-8 mm needle, pinch the skin gently to form a subcutaneous fold (or inject at 45-degree angle for thin subjects)

3. Insert the needle smoothly at a 90-degree angle (or 45 degrees for very lean subjects)

4. Inject the calculated volume at a steady, slow rate

5. Withdraw the needle and apply gentle pressure — do not rub, as rubbing accelerates absorption unpredictably

6. Dispose of the needle in an approved sharps container

Volume Calculation Examples

Research goal: 0.5 mg semaglutide, working concentration 1.0 mg/mL

Volume to inject = 0.5 mg divided by 1.0 mg/mL = 0.5 mL

Research goal: 0.25 mg semaglutide, working concentration 2.0 mg/mL

Volume to inject = 0.25 mg divided by 2.0 mg/mL = 0.125 mL

U-100 insulin syringes (1 mL) read in "units" where 100 units = 1.0 mL. For a working concentration of 1 mg/mL: 1 mg = 100 units on the syringe.

---

4. Dosage Tiers and Escalation Schedule from Research Literature

The following escalation schedules are derived directly from FDA package inserts and landmark clinical trial protocols. They represent the schedules used in the STEP/SUSTAIN/SELECT programs.

Ozempic Escalation (Type 2 Diabetes — SUSTAIN Program)

Key SUSTAIN data:

• •SUSTAIN-1 (PMID: 27633186): 0.5 mg and 1 mg reduced HbA1c by 1.45% and 1.55% vs. placebo (30 weeks, n=387)
• •SUSTAIN-7 (PMID unverified): 1 mg semaglutide superior to 1.5 mg dulaglutide — HbA1c reduction -1.5% vs. -1.1%; weight loss -6.5 kg vs. -3.0 kg

Wegovy Escalation (Weight Management — STEP Program)

The Wegovy escalation protocol is the most widely referenced in weight-loss research contexts:

This 16-week escalation reduces gastrointestinal adverse events (nausea, vomiting) that are common at therapeutic doses. In STEP trials, approximately 5% of participants discontinued due to GI side effects even with this schedule.

Key STEP data:

• •STEP-1 (PMID: 33567185): 2.4 mg/week produced mean 14.9% body weight reduction vs. 2.4% with placebo (68 weeks, n=1,961)
• •STEP-2 (PMID unverified): In T2D subjects, 9.6% weight reduction vs. 3.4% placebo (68 weeks)
• •STEP-3 (PMID unverified): Combined with intensive behavioral therapy — 16.0% mean weight reduction (68 weeks)
• •STEP-4 (PMID unverified): Withdrawal study confirmed weight regain of 6.9% at 1 year post-discontinuation, underscoring sustained treatment requirement

SELECT Trial (Cardiovascular Research)

The SELECT trial (PMID unverified, N=17,604) used the same 2.4 mg/week maintenance dose (Wegovy escalation protocol) in adults with established CV disease but without diabetes. Results:

• •20% relative risk reduction in MACE (major adverse cardiovascular events) vs. placebo
• •Median follow-up: 33.6 months
• •First GLP-1 agonist to demonstrate CV benefit independent of glycemic effect

---

5. Administration Timing and Injection Scheduling

Once-Weekly Timing Principles

Semaglutide's approximately 168-hour half-life means it reaches steady state within 4-5 weeks of once-weekly dosing. Key timing considerations from the FDA PI:

• •Day of week: Any day; consistency reduces variability in peak plasma concentrations
• •Time of day: No pharmacokinetic requirement (morning vs. evening makes no statistically significant difference per Ozempic PI)
• •Meal timing: Subcutaneous semaglutide can be administered without regard to meals (Rybelsus oral form must be taken 30 minutes before the first meal of the day on an empty stomach — this applies only to the tablet formulation)
• •Missed dose protocol: If a dose is missed and the next scheduled dose is 48+ hours away, administer as soon as possible. If fewer than 48 hours remain until the next dose, skip the missed dose and resume on the regular schedule

Injection Rotation Schedule (Practical Example)

For a researcher tracking weekly administrations on a consistent schedule:

• •Week 1: Right abdomen, upper quadrant
• •Week 2: Left abdomen, upper quadrant
• •Week 3: Right abdomen, lower quadrant
• •Week 4: Left abdomen, lower quadrant
• •Week 5: Right thigh
• •Week 6: Left thigh
• •(repeat cycle)

Documenting injection site in research logs prevents inadvertent same-site injection and allows detection of local reactions.

---

6. Handling, Storage, and Shelf Life After Reconstitution

Pre-Reconstitution (Lyophilized Vial)

Post-Reconstitution

Critical handling notes:

• •Never freeze reconstituted semaglutide — freezing disrupts the peptide structure and can cause irreversible aggregation
• •Protect from light — store vials wrapped in foil or in a dark refrigerator drawer; UV exposure accelerates degradation
• •Avoid temperature cycling — repeated freeze/thaw or warm/cold cycles significantly reduce potency
• •Discard if: solution becomes cloudy, particulates appear, or unusual discoloration develops
• •Each draw should use a fresh needle — reusing needles risks contamination even from the same vial

Stability Checklist Before Each Use

• •Clear solution (not cloudy)
• •No visible particulates
• •Color within expected range (colorless to pale yellow)
• •Vial within reconstitution date window
• •Septum intact (no visible puncture damage)

---

7. Research Use Documentation and Sourcing Considerations

Documentation Best Practices

Researchers working with semaglutide for in vivo or in vitro studies should maintain:

• •Chain of custody log: Vial lot number, supplier, receipt date, reconstitution date, researcher ID
• •COA (Certificate of Analysis): Purity 98%+ by HPLC; molecular weight confirmation by mass spectrometry
• •Injection log: Date, time, site, volume, dose, any observations
• •Storage temperature log: Continuous or spot-check refrigerator temperature monitoring

What to Look for in a Supplier

When evaluating research-grade semaglutide vendors, prioritize:

1. Third-party HPLC purity testing — Minimum 98% purity; 99%+ preferred for dose-sensitive in vivo work

2. Mass spectrometry confirmation — Verifies correct molecular identity (MW: 4113.58 g/mol for free base)

3. Endotoxin testing — Critical for any in vivo or cell culture application; should be below 1 EU/mg

4. Lot-specific COAs — Generic batch COAs that are not specific to your vial lot are a red flag

5. Sterile filtration documentation — Especially relevant for injectable applications

Peptides.SO indexes over 20 verified suppliers with real-time pricing. Compare current availability, HPLC purity data, and per-unit cost using our semaglutide supplier comparison tool.

For in-depth supplier reviews including quality benchmarks, see: Best Semaglutide Research Sources 2026

---

8. Price Comparison and Sourcing

Research-grade semaglutide pricing varies substantially across the vendor landscape. Based on current indexed data from peptides.so:

• •2 mg vials: Typically $30-$75 depending on supplier and purity tier
• •5 mg vials: Range from $60-$150
• •10 mg vials: Range from $120-$280

Per-milligram cost generally decreases with larger vials, but purity variance between suppliers can be significant. A 10 mg vial at $120 with 95% HPLC purity may represent less value than a $150 vial at 99%+ — particularly in dose-response research where potency consistency is critical.

Use our dosage calculator to estimate required vial quantities for your study protocol.

---

Summary: Semaglutide Research Protocol Reference Card

---

For research purposes only (RUO). Semaglutide sold by peptide research vendors is labeled and sold exclusively for laboratory research use. It has not been evaluated for safety or efficacy as a compounded product. FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus) requires a valid prescription from a licensed healthcare provider. This article draws entirely from published peer-reviewed literature and FDA-approved prescribing information. Peptides.SO does not provide medical advice, diagnose conditions, or recommend treatment.

Sources: Ozempic Prescribing Information (NDA 209637, rev. 2023); Wegovy Prescribing Information (NDA 215256, rev. 2023); Marso SP et al., SUSTAIN-6, NEJM 2016 (PMID unverified); Wilding JPH et al., STEP-1, NEJM 2021 (PMID: 33567185); Ryan DH et al., STEP-3, JAMA 2021 (PMID unverified); Rubino DM et al., STEP-4, JAMA 2021 (PMID unverified); Lincoff AM et al., SELECT, NEJM 2023 (PMID unverified).

> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.